The FDA Lifted the Clinical Hold on Solid Biosciences’ IGNITE DMD Phase 1/2 Trial Sending the Stock Price Over 131%
October 1, 2020
0
Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA Solid Biosciences (SLDB) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical hold placed on the Company’s IGNITE DMD Phase 1/2 clinical trial. The FDA had requested further manufacturing information, updated safety and efficacy . . . This content …